Female patients with pseudomyxoma peritonei: a single-institution clinicopathologic study of 35 cases.

PURPOSE: To explore clinicopathologic/prognostic aspects of pseudomyxoma peritonei (PMP). METHODS: We reviewed records of 35 female patients with PMP treated at a single institution. RESULTS: Patients' median age was 57.0 years (range 35.0-71.0 years). Their median pre-surgery level of carbohydrate antigen 19-9 (CA-199) was 80.95 U/ml (range 0.00-1,562.10 U/ml); of carbohydrate antigen 12-5 (CA-125), 44.00 U/ml (range 0.90-231.20 U/ml); and of carcinoembryonic antigen (CEA), 17.20 ng/ml (range 2.04-211.60 ng/ml). Of the 35 patients, 23 (65.7 %) underwent cytoreductive surgery (CRS) by gynecological oncologists and 12 (34.3 %) underwent non-CRS surgeries by general gynecologists or surgeons, including one patient who refused surgical treatment beyond a diagnostic laparoscopy. After surgery, 18 patients (51.4 %) had residual lesions, 11 (31.4 %) had complete lesion removal and 6 (17.1 %)had insufficient information on residual lesion; 21 (60.0 %) had appendiceal-based tumors and 12 (34.3 %) had ovarian-based tumors. Median follow-up time was 37 months (range 1-148 months), during which 28 patients (80.0 %) had relapsed. By the end of the study, 12 patients (34.3 %) died of PMP, 16 (45.7 %) survived with disease, and 7 (20 %) survived without disease. Median progress-free survival (PFS) was 12 months (range 0.5-114.0 months). Median overall survival time was 42 months (range 5-150 months). Ovarian tumor origin, post-surgery residual lesions, preoperative CA199 > 258.9 U/ml and CA125 > 70.6 U/ml were independent predictors of PFS. CONCLUSIONS: PMP is rare in women, and has a poor long-term survival rate. Multi-center cooperation to gather more cases is needed to explore its behavior and proper treatment.

Consolidation chemotherapy in advanced epithelial ovarian carcinoma: a prospective randomized controlled trial / 解放军医学杂志

Objective To evaluate the effects of consolidation chemotherapy on postponing the relapse in patients with advanced epithelial ovarian carcinoma. Methods 44 patients with advanced epithelial ovarian carcinoma treated in our hospital from March 2000 to April 2004 were enrolled. Clinical complete remission was achieved after standard treatments in all these patients, and they were randomly assigned into consolidation group and control group. Relapse rate and Disease-free Survival were analyzed. Results 22 patients were assigned to consolidation group, and 22 patients as control group. The latest follow up examination was done in July 2005. Relapse rate was 45.5% in consolidation group, and 59.1% in control group (P=0.365). Mean relapse time in consolidation group was 25.3?9.3 months, and was 16.9?6.7 months in control group (P=0.019). Mean Disease-free Survival was 31.9?14.8 months in consolidation group, and was 22.7?12.9 months, in control group (P=0.033). Kaplan-Meier Survival Analysis showed no significant difference P=0.22. Conclusion Consolidation chemotherapy may postpone tumor relapse and prolong Disease-free survival in patients with clinical complete remission advanced epithelial ovarian carcinoma. While it hasn′t been proved but the results in present study did not prove that consolidation chemotherapy could lower relapse rate or elevate survival rate. Further study is needed to achieve better results.